Aotai Bio announced that as of August 11, 2026, the company had repurchased 3.63 million shares, representing 4.57 percent of total share capital, for a total amount of 199 million yuan, at prices ranging from 41.88 yuan to 68.29 yuan per share. The repurchased shares will be cancelled to reduce registered capital. In the first quarter of 2026, the company achieved revenue of 195 million yuan and net profit attributable to the parent of 19.39 million yuan.
Hangzhou Alltest Biotech Co. Ltd. ACompany completed a 199 million yuan share buyback for cancellation, reducing share count and potentially boosting per-share metrics.
